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PResistin, Adiponectin, and Risk of Heart Failure
The Framingham Offspring Study
David S. Frankel, MD,* Ramachandran S. Vasan, MD,†‡ Ralph B. D’Agostino, SR, PHD,†
Emelia J. Benjamin, MD, SCM,†‡§ Daniel Levy, MD,† Thomas J. Wang, MD,†¶
James B. Meigs, MD, MPH†#
Boston and Framingham, Massachusetts; and Bethesda, Maryland
Objectives We tested the association of the adipokines resistin and adiponectin with incident heart failure.
Background Abnormal concentrations of adipokines may partially explain the association between obesity and heart failure.
Methods We related circulating adipokine concentrations to the incidence of heart failure in 2,739 participants in the Fra-
mingham Offspring Study.
Results During 6 years of follow-up, 58 participants developed new-onset heart failure. In proportional hazards models
(adjusting for age, sex, blood pressure, antihypertensive treatment, diabetes, smoking, total/high-density lipopro-
tein cholesterol ratio, prevalent coronary heart disease, valvular heart disease, left ventricular hypertrophy, and
estimated glomerular filtration rate) using the lowest third of the resistin distribution as the referent, the hazard
ratios for heart failure in the middle and top thirds were 2.89 (95% confidence interval [CI]: 1.05 to 7.92) and
4.01 (95% CI: 1.52 to 10.57), respectively (p  0.004 for trend). Additional adjustment for body mass index,
insulin resistance (measured with the homeostasis model), C-reactive protein, and B-type natriuretic peptide did
not substantively weaken this association (multivariable hazard ratios [HRs]: 2.62 and 3.74, p  0.007). In the
maximally adjusted model, each SD increment in resistin (7.45 ng/ml) was associated with a 26% increase in
heart failure risk (95% CI: 1% to 60%). Concentrations of adiponectin were not associated with heart failure
(multivariable HRs: 0.87 and 0.97, p  0.9).
Conclusions Increased circulating concentrations of resistin were associated with incident heart failure, even after accounting
for prevalent coronary heart disease, obesity, and measures of insulin resistance and inflammation. The findings
suggest a role for resistin in human disease and a novel pathway to heart failure. (J Am Coll Cardiol 2009;53:
754–62) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.073d
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geart failure is a common health problem that is increasing
n prevalence (1). Despite improvements in treatment, heart
ailure remains a highly lethal disease (2). Identification of
isk factors for the development of heart failure could aid
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Manuscript received April 9, 2008; revised June 11, 2008, accepted July 1, 2008.evelopment of prevention strategies. Numerous risk factors
ave been well established, including age, coronary heart
isease (CHD), hypertension, valvular heart disease, left
entricular hypertrophy, diabetes, and obesity (3). Recent
nvestigations have highlighted the association of over-
eight and lesser degrees of obesity with increased inci-
ence of heart failure (4). Insulin resistance is likely to
ccount for some, but not all of this association (5).
See page 763
The mechanisms by which insulin resistance and obesity
romote heart failure risk remain uncertain. Proposed
echanisms include a systemic inflammatory state with
ncreased concentrations of circulating inflammatory medi-
tors such as C-reactive protein, plasminogen activator
nhibitor-1, tumor necrosis factor-alpha, interleukin-6, an-
iotensinogen, vascular endothelial growth factor, and se-
um amyloid A3 (6). Increased circulating concentrations of
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March 3, 2009:754–62 Inflammatory Adipokines and HFumor necrosis factor-, interleukin-6, and C-reactive pro-
ein have been associated with increased incidence of heart
ailure (7,8).
Several novel proteins secreted by adipocytes (adipo-
ines), including resistin and adiponectin, have pro- and
nti-inflammatory properties and are correlated with con-
entrations of plasma cytokines (9,10). Like other inflam-
atory markers, greater concentrations of resistin have been
ssociated with CHD in some (9,11–13) but not in other
tudies (14,15). A single, cross-sectional analysis of patients
ith established heart failure found that greater concentrations
f resistin correlated with increased disease severity and also
redicted adverse cardiac outcomes (16). However, resistin has
et to be examined as a predictor of new-onset heart failure in
he community.
Concentrations of adiponectin are decreased in insulin
esistance and obesity, an inverse association that suggests
diponectin may mitigate the adverse effects of circulating
nflammatory mediators, as has been demonstrated in
xperimental models (17,18). Low concentrations of
diponectin have been associated with increased risk of
HD (19) and inconsistently related to heart failure
ncidence (20,21). In patients with established heart
ailure, low adiponectin has paradoxically been associated
ith decreased mortality (21,22). Thus, the role of
diponectin in the development of heart failure remains
ncertain as well.
With this background in mind, we examined the associ-
tion of circulating resistin and adiponectin concentrations
ith the development of heart failure in a community-based
ample. We hypothesized that greater concentrations of
esistin and lower concentrations of adiponectin would be
ssociated with an increased risk of heart failure. Addition-
lly, we postulated that this association would be attenuated
y adjustment for associated variations in obesity, insulin
esistance, and inflammation that constitute potential me-
iatory mechanisms.
ethods
tudy participants. The Framingham Offspring Study is a
ommunity-based, prospective, observational study of car-
iovascular disease and its risk factors. The study began in
971 with the enrollment of 5,124 participants who were
he children of the original Framingham Heart Study
ohort and the spouses of these children. Members of the
ffspring cohort are white and of mixed European ancestry
23). During the seventh examination cycle (1999 to 2001;
he baseline examination for the present study), 3,539
articipants underwent standardized medical history, phys-
cal examination, 12-lead electrocardiogram, and analysis of
asting blood samples. We excluded 32 participants with
revalent heart failure at baseline. Because we began mea-
uring adipokine concentrations part way through the sev-
nth examination cycle, an additional 768 participants with
issing adipokine concentrations were excluded, leaving i,739 individuals for analysis.
articipants not included in the
nalysis were older with slightly
reater levels of CHD risk factors
han those included. The study
rotocol was approved by the In-
titutional Review Board of the
oston University School of Med-
cine, and all participants provided
ritten informed consent.
ovariate definitions and labo-
atory methods. We measured
eight, weight, and waist cir-
umference by using a standard-
zed protocol. Body mass index
BMI) was calculated as the
eight in kilograms divided by the square of the height in
eters (kg/m2). The examination blood pressure was taken
s the mean of 2 physician-obtained measurements after the
articipant had been seated for at least 5 min. We defined
iabetes as a fasting plasma glucose 125 mg/dl or treat-
ent with blood glucose-lowering medications. Coronary
eart disease was defined by standard Framingham Heart
tudy criteria as any of new-onset angina, coronary insuf-
ciency, or fatal or nonfatal myocardial infarction. We
efined valvular heart disease by the presence of a systolic
urmur of grade 3/6 or greater or any diastolic murmur
24). We used a continuously distributed electrocardio-
raphic metric of left ventricular hypertrophy by summing
he voltages of the R-wave in lead aVL and the S-wave in
ead V3 (25). Those who reported smoking cigarettes
egularly during the year before the examination were
onsidered current smokers.
Participants fasted overnight to provide blood specimens.
amples were frozen at 80°C until assay. Laboratory
ethods for creatinine, glucose, insulin, and lipid assays
ave been published previously (26,27). Assay coefficients of
ariation were 3% for glucose and 10% for insulin. We
alculated insulin resistance with the homeostasis model
sing the following validated formula: HOMA-IR  (fast-
ng glucose [mmol/l]  fasting insulin [U/ml])/22.5
28,29). C-reactive protein was measured with an immuno-
recipitation assay (IncStar, Stillwater, Minnesota). We
stimated the glomerular filtration rate as follows: (186 
serum creatinine]  1.154)  ([age]  0.203)  (0.742 if
emale) (30). The urine albumin/creatinine ratio (UACR)
as assessed at exam 6 from a single void urine sample. The
rine albumin concentration was measured by immunotur-
imetry (Tina-quant Albumin assay, Roche Diagnostics,
ndianapolis, Indiana) and the urine creatinine concentra-
ion by the use of a modified Jaffe method. Plasma
nterleukin-6, tumor necrosis factor-alpha, resistin, and
otal adiponectin were measured by enzyme-linked immuno-
orbent assay (R&D Systems, Minneapolis, Minnesota)
7). Intra-assay coefficients of variation were 3.1% for
Abbreviations
and Acronyms
BMI  body mass index
CHD  coronary heart
disease
CI  confidence interval
HDL  high-density
lipoprotein
HOMA-IR  insulin
resistance measured with
the homeostasis model
HR  hazard ratio
UACR  urine albumin/
creatinine rationterleukin-6, 6.6% for tumor necrosis factor-, 5.8% for
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Inflammatory Adipokines and HF March 3, 2009:754–62diponectin, and 9.0% for resistin. Plasma B-type natri-
retic peptide was not measured at examination cycle 7, so
e used measurements from examination cycle 6 using a
igh-sensitivity, noncompetitive immunoradiometric assay
Shionogi, Osaka, Japan) (8).
efinition of heart failure. All new heart failure events
ccurring from baseline through end of follow-up in De-
ember 2005 were adjudicated by a panel of 3 physicians,
ccording to previously published Framingham criteria (31).
pecifically, the simultaneous presence of either 2 major or
major plus 2 minor criteria, in the absence of an alternative
xplanation for the symptoms and signs, was required to
ake the diagnosis of heart failure. Major criteria included
aroxysmal nocturnal dyspnea, orthopnea, jugular venous
istension, hepatojugular reflux, pulmonary rales, radio-
raphic evidence of cardiomegaly, acute pulmonary edema,
hird heart sound, central venous pressure 16 cm of water,
nd weight loss 4.5 kg during the first 5 days of treatment
or suspected heart failure. Minor criteria included bilateral
nkle edema, nocturnal cough, dyspnea on ordinary exer-
ion, hepatomegaly, pleural effusion, and heart rate 120
eats/min. Of 58 participants with new heart failure events,
4 were hospitalized with heart failure and 4 were not
ospitalized but were diagnosed with heart failure based on
hysician office visits.
tatistical analysis. We classified participants into thirds
f the distribution of resistin and adiponectin. The primary
nalyses were conducted for pooled sexes because of low
tatistical power for sex-specific analyses given the modest
umber of heart failure events on follow-up. We used
nalysis of variance or Mantel-Haenszel tests of trend to
ssess differences in mean risk factor levels or proportions
cross adipokine strata, and Spearman correlation coeffi-
ients to assess correlations among risk factors. For analy-
is of variance tests, levels of HOMA-IR, C-reactive pro-
ein, B-type natriuretic peptide, and UACR were log-
ransformed to reduce skewness; we present the results by
aking the anti-logarithm for ease of interpretation. We
onstructed Kaplan-Meier curves to illustrate survival free of
eart failure for each adipokine stratum and tested differ-
nces in survival across strata with the log-rank test. We
sed a nested series of Cox proportional hazards regression
odels (after confirming the assumption of proportionality
f hazards) to test the hypothesis that greater concentrations
f resistin and lower concentrations of adiponectin were
ssociated with an increased risk of heart failure after
djustment for potentially confounding heart failure risk
actors. Cox models provided hazard ratios (HRs) and 95%
onfidence intervals (CIs) for incident heart failure condi-
ioned on baseline exposures. Models testing incidence of
eart failure across increasing thirds of adipokines were
djusted hierarchically for: 1) age and sex; 2) age, sex,
ystolic blood pressure, antihypertensive treatment, diabe-
es, smoking, total/high-density lipoprotein (HDL) choles-
erol ratio, prevalent coronary heart disease, valvular heart
isease, left ventricular hypertrophy, and estimated glomer- dlar filtration rate; and 3) the variables in model 2 and BMI,
OMA-IR, C-reactive protein, and B-type natriuretic
eptide, individually and together in a maximally adjusted
odel. Tests of trend across HRs were assessed in models
ith the use of ordinal increments to represent adipokine
trata. We further examined dose-response relations of
dipokines and heart failure in the maximally adjusted
odel using penalized splines (32), and in multivariable
djusted analyses, we tested the association of heart failure
ith adipokines as continuously distributed, using per SD
ncrease (7.45 ng/ml for resistin and 6.32 g/ml for adi-
onectin) as the unit of exposure.
ubsidiary analyses. Because CHD at baseline or a new
HD event over follow-up would be expected to be a
otent risk factor for new-onset heart failure, in additional
ubsidiary analyses we excluded all baseline and new cases of
HD (92 cases) occurring during the course of follow-up.
iven 58 heart failure events, the full model with 15
redictor variables may have been overparameterized. To
ddress this concern, we repeated the analyses in models
hat substituted the Framingham coronary heart disease risk
core for its individual components (age, systolic blood
ressure, antihypertensive treatment, diabetes, current cig-
rette smoking, and total and HDL cholesterol) (33).
ecause interleukin-6 and tumor necrosis factor-alpha are
nflammatory markers that have been associated with heart
ailure, we substituted each one for C-reactive protein (7).
In addition to accounting for renal function using esti-
ated glomerular filtration rate, we also adjusted models for
ACR. However, UACR was measured 4 years before the
ther baseline measures in this study, and data were not
omplete (2,241 had UACR levels), so results should be
nterpreted with caution. We also repeated the analyses
sing waist circumference instead of BMI, because a larger
aist circumference may be more reflective of abnormal
dipocyte function and has been shown to predict cardio-
ascular events in normal-weight, overweight, and mildly
bese subjects (34). Although sex differences were not a
ypothesis of the present investigation, we repeated our
nalyses using sex-specific thirds of the adipokine distribu-
ions; results were identical to those of the pooled-sex
nalyses, so we present only the latter. Finally, we assessed
he association of adipokine levels with incident CHD,
djusted as in Model 2, with prevalent cases of CHD
emoved from the analysis. Analyses were performed using
AS software (version 8.1, SAS Institute, Cary, North
arolina). We considered p values 0.05 to indicate statis-
ical significance.
esults
aseline characteristics. Characteristics of the study par-
icipants across strata of resistin and adiponectin are dis-
layed in Table 1, and the frequency distribution of partic-
pants by concentrations of resistin and adiponectin are
isplayed in Figures 1E and 1F. The prevalence of common
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March 3, 2009:754–62 Inflammatory Adipokines and HFeart failure risk factors increased with increasing concen-
rations of resistin and decreased with increasing concen-
rations of adiponectin. Levels of BMI, waist circumference,
OMA-IR, and C-reactive protein were positively corre-
ated with concentrations of resistin and inversely correlated
ith concentrations of adiponectin (Table 2). Concentra-
ions of resistin and adiponectin were inversely correlated
ith each other.
dipokines and heart failure risk. Fifty-eight participants
25 women; 19 with CHD at baseline) developed new-onset
eart failure over a mean follow-up of 6 years (cumulative
ncidence, 2.12%). Survival free of heart failure decreased in
reater strata compared with lower strata of resistin (p 
.0001) (Fig. 1A). The HR for heart failure increased across
trata of resistin, adjusted for age and sex (Table 3).
ncreased risk associated with greater resistin concentrations
ersisted after further adjustment for systolic blood pressure,
ntihypertensive treatment, diabetes, smoking, total/HDL
holesterol ratio, prevalent CHD, valvular heart disease, left
entricular hypertrophy, and estimated glomerular filtration
ate. The resistin-heart failure association was maintained
fter further adjustment for BMI, HOMA-IR, C-reactive
aseline Characteristics of Study Participants by Thirds of the Adip
Table 1 Baseline Characteristics of Study Participants by Third
Resistin
Third 1,
Range
1.2–10.9
(ng/ml)
Third 2,
Range
11.0–14.9
(ng/ml)
Thir
Ran
15.0–
(ng/
n 904 923 912
Female (%) 54 53 53
Age (yrs) 60 (9) 61 (9) 63 (1
Systolic blood pressure (mm Hg) 126 (19) 126 (19) 130 (1
Treatment with antihypertensive
medications (%)
26 32 42
Type 2 diabetes (%) 8.1 10.0 15.0
Current cigarette smoking (%) 13 12 15
Serum total/high-density lipoprotein
cholesterol ratio
3.8 (1.2) 4.1 (1.4) 4.2
Baseline prevalent coronary heart
disease (%)
8.3 6.9 10.1
Valvular heart disease (%) 1.8 2.3 3.6
Electrocardiographic left ventricular
hypertrophy (mm)
12.2 (5.1) 12.5 (5.3) 12.9
Body mass index (kg/m2) 27 (5) 28 (5) 29 (6
Waist circumference (cm) 97 (13) 100 (14) 103 (1
Insulin resistance with the
homeostasis model†
3.2 (1.9) 3.6 (2.0) 4.0
C-reactive protein (mg/ml)† 2.8 (3.2) 4.0 (5.2) 6.1
Plasma B-type natriuretic peptide
(pg/ml)†
13 (17) 15 (18) 17 (2
Estimated glomerular filtration rate
(ml/min/1.73 m2)
89 (18) 85 (18) 80 (2
Urine albumin/creatinine ratio
(mg/g)†
5.0 (5.1) 5.6 (4.9) 6.8
Adiponectin (g/ml)† 8.9 (1.9) 8.4 (1.9) 8.0
Resistin (ng/ml)† — — —
p values indicate significance for trend across strata of resistin. †Antilogarithm. Standard deviatrotein, and B-type natriuretic peptide (Table 3). Analyses Ef splines modeling resistin as a continuous variable and
sing the maximally adjusted model suggested a linear dose
esponse relationship over the lower end of the resistin
istribution where the majority of participants contributed
ata, arguing against outlying values driving the association
Fig. 1C). Modeled as a continuous covariate, the HRs per
D increment in resistin were 1.45 (95% CI: 1.16 to 1.82),
.36 (95% CI: 1.09 to 1.69), and 1.26 (95% CI: 0.99 to
.60) after adjustment as in models 1, 2, and 3E,
espectively.
Adiponectin was not associated with incident heart fail-
re in any of the models examined (Figs. 1B and 1D, Table
). With 58 heart failure events, our investigation had 80%
ower at an alpha of 0.05 to detect an HR for heart failure
s small as 0.39 for the greatest adiponectin third compared
ith the lowest. Continuously distributed concentrations of
diponectin were not associated with risk of heart failure
ither; in the maximally adjusted model, the HR per SD
ncrease was 0.96 (95% CI: 0.67 to 1.36).
ubsidiary analyses. After exclusion of 231 baseline and 92
ew cases of CHD occurring during the course of follow-
p, there remained 26 new cases of heart failure for analysis.
e Distributions*
the Adipokine Distributions*
p Value
Adiponectin
p Value
Third 1,
Range
0.7–6.4
(g/ml)
Third 2,
Range
6.5–11.0
(g/ml)
Third 3,
Range
11.1–59.9
(g/ml)
920 900 919
0.9 29 52 79 0.0001
0.0001 60 (10) 61 (9) 62 (9) 0.0001
0.0001 128 (17) 127 (19) 126 (20) 0.09
0.0001 38 34 28 0.0001
0.0001 17.7 11.8 3.6 0.0001
0.3 15 13 12 0.4
0.0001 4.7 (1.4) 4.1 (1.1) 3.3 (1.0) 0.0001
0.05 12.1 8.2 5.0 0.0001
0.05 2.1 2.5 3.1 0.4
0.04 13.7 (5.1) 12.5 (5.0) 11.4 (5.2) 0.0001
0.0001 30 (5) 29 (5) 26 (5) 0.0001
0.0001 105 (13) 101 (13) 94 (14) 0.0001
0.0001 5.0 (1.9) 3.6 (1.8) 2.6 (1.7) 0.0001
0.0001 4.5 (6.3) 4.9 (10.9) 3.6 (5.8) 0.004
0.0004 13 (19) 15 (21) 18 (19) 0.0001
0.0001 85 (18) 85 (20) 84 (20) 0.2
0.002 4.6 (5.4) 5.7 (5.4) 7.3 (4.5) 0.0001
0.0008 — — — —
— 13.6 (1.5) 13.1 (1.5) 12.4 (1.5) 0.0001
in parenthesis.okin
s of
d 3,
ge
110.0
ml)
0)
9)
(1.3)
(5.0)
)
4)
(1.9)
(12.1)
3)
1)
(5.5)
(1.3)xclusion of all CHD from the maximally adjusted model
d
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Inflammatory Adipokines and HF March 3, 2009:754–62id not substantively alter the results (Table 3). Similarly,
ubstituting the Framingham coronary heart disease risk
core for its individual components did not alter our results;
or resistin, HR: 2.81 (95% CI: 1.02 to 7.75) and 4.20 (95%
I: 1.62 to 10.94) in the second and third strata of model
E, respectively (p  0.002 for trend). Adjustment for
nterleukin-6 or tumor necrosis factor-alpha instead of
Figure 1 Heart Failure Free Survival by Adipokine Concentratio
(A and B) Kaplan-Meier curves are shown for survival free of heart failure accordin
0.7 for adiponectin). (C and D) Dose-response relationships between resistin and
imally adjusted as in Model 3E) (Table 3) using penalized splines. Dashed lines re
illustrate the frequency distribution of study subjects across concentrations of res
of heart failure across the range where the greatest number of subjects contribute-reactive protein did not significantly change results ei- mher. For instance, substituting interleukin-6 for C-reactive
rotein in model 3E yielded an HR for resistin in the top
ersus bottom third of 3.82 (95% CI: 1.46 to 10.03; p 
.005), and substituting tumor necrosis factor-alpha for
-reactive protein yielded an HR of 4.11 (95% CI: 1.56 to
0.08; p  0.002). Further adjustment of model 3E for
ACR did not alter the results; the HR for resistin in the
aseline thirds of resistin and adiponectin (log-rank p  0.0001 for resistin, p 
ectin and heart failure are illustrated with generalized additive Cox models (max-
t 95% confidence limits of the resulting hazard ratios. (E and F) Histograms
nd adiponectin. There is a linear dose-response relationship of resistin with risk
ation on resistin concentration.n
g to b
adipon
presen
istin a
informiddle third was 4.31 (95% CI: 1.23 to 15.13) and in the
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March 3, 2009:754–62 Inflammatory Adipokines and HFop third 5.29 (95% CI: 1.53 to 18.23; p  0.008).
ubstituting waist circumference for BMI also yielded
imilar results. Using waist circumference in model 3A, we
ound that the HR for resistin in the top versus bottom third
as 4.02 (95% CI: 1.55 to 10.42; p  0.003) and in model
E was 3.80 (95% CI: 1.45 to 9.98; p  0.005). Adiponec-
in remained unassociated with heart failure after excluding
HD, substituting the Framingham coronary heart disease
isk score for its individual components, substituting
nterleukin-6 for C-reactive protein, substituting tumor
ecrosis factor-alpha for C-reactive protein, adding UACR,
ubstituting waist circumference for BMI, and using sex-
pecific thirds (p  0.6, 0.4, 0.8, 0.8, 0.9, 0.9, and 0.2 for
rends across HR, respectively).
elation of Age- and Sex-Adjusted Levelsf Resistin and Adipon ctin to Each Other and to HOMA-IR, CRP, a
Table 2 Relation of Age- and Sex-Adjusted Levelsof Resistin and Adiponectin to Each Other and to HOM
Spearman
Correlation C
Body mass index (kg/m2) 0.1
Waist circumference (cm) 0.1
Insulin resistance measured with the homeostasis model 0.1
CRP (mg/ml) 0.2
Plasma BNP (pg/ml) 0.0
Estimated glomerular filtration rate (ml/min/1.73 m2) 0.2
Urine albumin/creatinine ratio (mg/g) 0.0
Adiponectin (g/ml) 0.0
Resistin (ng/ml) —
pearman rank correlation coefficients are provided for the correlation between adipokine levels
BNP  B-type natriuretic peptide; CRP  C-reactive protein; HOMA-IR  insulin resistance mea
ested Cox Proportional Hazard Models Testing the Incidence of H
Table 3 Nested Cox Proportional Hazard Models Testing the In
Resistin (Thi
1 2
Number of heart failure events 6 16
Model 1* 1.00 2.22
(0.87–5.69) (1.6
Model 2† 1.00 2.89
(1.05–7.92) (1.5
Model 3A: Model 2  BMI 1.00 2.77
(1.01–7.63) (1.4
Model 3B: Model 2  HOMA-IR 1.00 2.56
(0.92–7.09) (1.4
Model 3C: Model 2  CRP 1.00 2.86
(1.04–7.86) (1.4
Model 3D: Model 2  BNP 1.00 2.93
(1.07–8.05) (1.5
Model 3E: Model 2  BMI  HOMA-IR 1.00 2.62
 CRP  BNP (0.95–7.27) (1.4
Model 3F: Model 3E excluding participants 1.00 2.87
with CHD at baseline or during follow-up (0.57–14.52) (1.0
azard ratios for incident heart failure are provided with confidence intervals in parentheses. p va
ge, sex, systolic blood pressure, antihypertensive treatment, diabetes, smoking, total/high-dens
stimated glomerular filtration rate.
BMI  body mass index; CHD  coronary heart disease; other abbreviations as in Table 2.Neither resistin nor adiponectin were associated with
ncident CHD. For example, when adjusted as in model 2,
he HR for CHD in the middle third of the resistin
istribution was 0.76 (95% CI: 0.44 to 1.30) and in the top
hird 0.82 (95% CI: 0.49 to 1.38) (p  0.5 for trend). For
diponectin, the HR for CHD in the middle third of the
istribution was 0.73 (95% CI: 0.43 to 1.22) and in the top
hird was 0.70 (95% CI: 0.37 to 1.32) (p  0.2 for trend).
iscussion
rincipal findings. We observed that greater circulating
esistin was strongly associated with increased risk of new-
nset heart failure during 6 years of follow-up of a
ommunity-based sample. The association of resistin with
NP
CRP, and BNP
in (ng/ml) Adiponectin (g/ml)
ient p Value
Spearman Rank
Correlation Coefficient p Value
0.0001 0.33 0.0001
0.0001 0.35 0.0001
0.0001 0.43 0.0001
0.0001 0.12 0.0001
0.0002 0.24 0.0001
0.0001 0.04 0.03
0.003 0.16 0.0001
0.0001 — —
— 0.09 0.0001
tilogarithm of variables. p values were calculated with the use of analysis of variance.
ith the homeostasis model.
Failure Across Adipokine Strata
ce of Heart Failure Across Adipokine Strata
Adiponectin (Third)
p Value 1 2 3 p Value
22 19 17
0.0008 1.00 0.84 0.64 0.2
5) (0.45–1.57) (0.32–1.27)
0.004 1.00 0.90 0.79 0.6
.57) (0.47–1.70) (0.36–1.76)
0.007 1.00 0.93 0.89 0.8
7) (0.49–1.76) (0.40–1.97)
0.005 1.00 1.03 1.04 0.9
.09) (0.53–1.99) (0.45–2.39)
0.005 1.00 0.88 0.79 0.6
.36) (0.47–1.67) (0.36–1.75)
0.004 1.00 0.80 0.72 0.4
.73) (0.41–1.53) (0.32–1.60)
0.007 1.00 0.87 0.97 0.9
9) (0.44–1.73) (0.42–2.22)
0.03 1.00 1.39 1.38 0.6
.13) (0.46–4.26) (0.39–4.90)
dicate significance for trend across strata of adipokine. *Adjusted for age and sex. †Adjusted for
rotein cholesterol ratio, prevalent CHD, valvular heart disease, left ventricular hypertrophy, andnd B
A-IR,
Resist
Rank
oeffic
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ciden
rd)
3
36
3.91
3–9.3
4.01
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3.91
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Inflammatory Adipokines and HF March 3, 2009:754–62eart failure persisted after adjustment for established heart
ailure risk factors, obesity, markers of insulin resistance and
nflammation, and concentrations of B-type natriuretic
eptide and after exclusion of prevalent and incident CHD.
e did not find that either lower or higher concentrations
f adiponectin were associated with new-onset heart failure.
ossible mechanisms. Little is currently understood about
he role of resistin in the pathophysiology of cardiovascular
iseases. In cross-sectional analysis, resistin has been shown
o be associated with the degree of atherosclerosis in
umans, as measured by coronary artery calcification (9). In
case-control study of 185 women with angiographically
onfirmed CHD and 227 population-based controls, the
ultivariable risk factor-adjusted odds ratio for CHD for
omen in the greatest compared with lowest quintile of
lasma resistin concentrations was 3.19 (95% CI: 1.44 to
.10, p 0.001) but, after adjustment for plasma C-reactive
rotein concentrations, the association was no longer sig-
ificant (odds ratio: 1.80; 95% CI: 0.69 to 4.69; p  0.23)
11). These findings suggest the hypothesis that increased
esistin could lead to heart failure by promoting CHD with
ubsequent ischemic left ventricular dysfunction, perhaps
ediated by vascular inflammatory processes. However, in
ur analysis, adjustment for baseline CHD or exclusion of
aseline and incident CHD events did not weaken the
ssociation between resistin and heart failure, suggesting
hat resistin-associated CHD is not the principal mecha-
ism mediating the association with risk of heart failure.
Resistin is expressed by adipocytes in mice, where it has
een shown to increase resistance to insulin (hence its name)
35,36). In humans, resistin is expressed in adipocytes, and
o an even greater extent in macrophages (37). Resistin has
een associated with markers of inflammation, including
-reactive protein, tumor necrosis factor-alpha, and
nterleukin-6, which have in turn been shown to predict
eart failure incidence (7,9). This suggests that resistin may
ead to heart failure by promoting insulin resistance and
nflammation. In our analysis, greater concentrations of
esistin were associated with greater degrees of insulin
esistance and greater concentrations of C-reactive protein
t baseline. However, adjustment for insulin resistance and
nflammatory markers did not attenuate the association of
esistin with heart failure, and resistin appeared to add to
he risk of heart failure associated with obesity, insulin
esistance, and inflammation. The data suggest that resistin
ay promote heart failure via mechanisms independent of
nsulin resistance and inflammation.
Neither high nor low concentrations of adiponectin
ere associated with new-onset heart failure in our study.
he role of adiponectin in the pathophysiology of car-
iovascular diseases is likely complex. Whereas low
oncentrations of adiponectin have been associated with
ncreased risk of incident CHD in healthy participants
19), high concentrations of adiponectin have been asso-
iated with increased severity of disease and adverse
utcomes in patients with established heart failure, pre- aumably serving as a marker of cachexia observed in
dvanced disease (21,22,38). Although 1 cross-sectional
tudy showed adiponectin concentrations to be greater in
atients with heart failure compared with control patients
21), a prospective cohort study of elderly, Swedish men
ailed to detect an association between adiponectin con-
entrations and heart failure incidence (20).
Obesity may contribute to heart failure by additional
echanisms independent of adipokine signaling, including
eurohormonal activation and increased oxidative stress
39,40), infiltration of myocytes with free fatty acids (41),
nd B-type natriuretic peptide depletion (42). Obesity is
lso associated with CHD morbidity and mortality (43), but
e accounted for this possibility by removing prevalent and
ncident cases of CHD in subsidiary analyses.
trengths and limitations. The strengths of our study
nclude a large, community-based sample assessed in which
e used standardized clinical measures and biomarker assays
ith good precision. Further, we used standardized meth-
ds for ascertainment of heart failure cases; 93% were events
hat led to hospitalization. The adiponectin assay used in
he current investigation measured total adiponectin. It has
een suggested that high-molecular weight adiponectin may
e the more biologically active form. For example, when
ompared with total adiponectin, high-molecular weight
as been more strongly associated with insulin resistance
44), metabolic syndrome (45), and the presence of coronary
rtery disease in diabetic patients (46). However, other
vidence suggests that total adiponectin may be more
trongly associated with insulin sensitivity and lipid profile,
oth at baseline and in response to physical training (47). It
s thus unclear whether high-molecular weight adiponectin
s more biologically relevant than total adiponectin. It is also
ossible that a small association between adiponectin and
eart failure was not detected secondary to power limita-
ions, especially in the subsidiary analysis excluding partic-
pants with baseline or incident CHD, where the number of
nd points was particularly limited. Additionally, our study
emonstrated an association between resistin and heart
ailure but does not establish causality. The ability to
peculate and gain insight into the potential mechanisms
inking resistin and heart failure is limited by the small
umber of end points, particularly when participants with
revalent CHD were excluded. Finally, our study sample
as almost exclusively white and middle-aged to elderly,
imiting generalizability of these findings to other ethnic
nd age groups.
onclusions
n our community-based sample, we found that increased
lasma concentrations of resistin were associated with sub-
equent development of heart failure even after accounting
or obesity, insulin resistance, inflammation, and concurrent
nd incident CHD. Levels of adiponectin were not associ-
ted with incident heart failure. The specific mechanism
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lucidated, but our findings suggest that novel mechanisms
romoting heart failure remain yet to be discovered.
cknowledgments
he authors thank Peter Shrader, MS, for assistance with
he statistical analyses and David M. Nathan, MD, for
ssistance with the insulin assays.
eprint requests and correspondence: Dr. James B. Meigs,
eneral Medicine Division, Massachusetts General Hospital, 50
taniford Street, 9th Floor, Boston, Massachusetts 02114. E-mail:
meigs@partners.org.
EFERENCES
1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke
statistics—2007 update: a report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Circulation
2007;115:e69–171.
2. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure
incidence and survival in a community-based population. JAMA
2004;292:344–50.
3. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK.
Risk factors for congestive heart failure in US men and women:
NHANES I epidemiologic follow-up study. Arch Intern Med 2001;
161:996–1002.
4. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart
failure. N Engl J Med 2002;347:305–13.
5. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin
resistance and risk of congestive heart failure. JAMA 2005;294:
334–41.
6. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovas-
cular disease. Circ Res 2005;96:939–49.
7. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers
and risk of heart failure in elderly subjects without prior myocardial
infarction: the Framingham Heart Study. Circulation 2003;107:
1486–91.
8. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels
and the risk of cardiovascular events and death. N Engl J Med
2004;350:655–63.
9. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ.
Resistin is an inflammatory marker of atherosclerosis in humans.
Circulation 2005;111:932–9.
0. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of
C-reactive protein with adiponectin in blood stream and adipose
tissue. Circulation 2003;107:671–4.
1. Pischon T, Bamberger CM, Kratzsch J, et al. Association of plasma
resistin levels with coronary heart disease in women. Obes Res
2005;13:1764–71.
2. Al-Daghri N, Chetty R, McTernan PG, et al. Serum resistin is
associated with C-reactive protein & LDL cholesterol in type 2
diabetes and coronary artery disease in a Saudi population. Cardiovasc
Diabetol 2005;4:10.
3. Ohmori R, Momiyama Y, Kato R, et al. Associations between serum
resistin levels and insulin resistance, inflammation, and coronary artery
disease. J Am Coll Cardiol 2005;46:379–80.
4. Lim S, Koo BK, Cho SW, et al. Association of adiponectin and
resistin with cardiovascular events in Korean patients with type 2
diabetes: The Korean atherosclerosis study (KAS). A 42-month
prospective study. Atherosclerosis 2008;196:398–404.
5. Yaturu S, Daberry RP, Rains J, Jain S. Resistin and adiponectin levels
in subjects with coronary artery disease and type 2 diabetes. Cytokine
2006;34:219–23.
6. Takeishi Y, Niizeki T, Arimoto T, et al. Serum resistin is associated
with high risk in patients with congestive heart failure—a novel link
between metabolic signals and heart failure. Circ J 2007;71:460–4.
7. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial
adhesion molecules: adipocyte-derived plasma protein adiponectin.
Circulation 1999;100:2473–6. 48. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein,
adiponectin, suppresses lipid accumulation and class A scavenger
receptor expression in human monocyte-derived macrophages. Circu-
lation 2001;103:1057–63.
9. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB.
Plasma adiponectin levels and risk of myocardial infarction in men.
JAMA 2004;291:1730–7.
0. Ingelsson E, Riserus U, Berne C, et al. Adiponectin and risk of
congestive heart failure. JAMA 2006;295:1772–4.
1. George J, Patal S, Wexler D, et al. Circulating adiponectin concen-
trations in patients with congestive heart failure. Heart 2006;92:
1420–4.
2. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass
index, and mortality in patients with chronic heart failure. Circulation
2005;112:1756–62.
3. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP.
An investigation of coronary heart disease in families. The Framing-
ham offspring study. Am J Epidemiol 1979;110:281–90.
4. Cupples L, D’Agostino, RB. Section 34: Some risk factors related to
the annual incidence of cardiovascular disease and death using pooled
repeated biennial measurements: Framingham Heart Study, 30-year
follow-up. Washington, DC: U.S. Department of Commerce, 1988.
5. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic
detection of left ventricular hypertrophy by the simple QRS voltage-
duration product. J Am Coll Cardiol 1992;20:1180–6.
6. Keaney JF Jr., Larson MG, Vasan RS, et al. Obesity and systemic
oxidative stress: clinical correlates of oxidative stress in the Framing-
ham Study. Arterioscler Thromb Vasc Biol 2003;23:434–9.
7. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia,
hyperglycemia, and impaired hemostasis: the Framingham Offspring
Study. JAMA 2000;283:221–8.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC. Homeostasis model assessment: insulin resistance and
beta-cell function from fasting plasma glucose and insulin concentra-
tions in man. Diabetologia 1985;28:412–9.
9. Balkau B, Charles MA. Comment on the provisional report from the
WHO consultation. European Group for the Study of Insulin Resis-
tance (EGIR). Diabet Med 1999;16:442–3.
0. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the
Modification of Diet in Renal Disease Study Group. A more accurate
method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Ann Intern Med 1999;130:461–70.
1. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural
history of congestive heart failure: the Framingham study. N Engl
J Med 1971;285:1441–6.
2. Hastie T, Tibshirani R. Generalized additive models for medical
research. Stat Methods Med Res 1995;4:187–96.
3. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H,
Kannel WB. Prediction of coronary heart disease using risk factor
categories. Circulation 1998;97:1837–47.
4. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circum-
ference, and health risk: evidence in support of current National
Institutes of Health guidelines. Arch Intern Med 2002;162:2074–9.
5. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links
obesity to diabetes. Nature 2001;409:307–12.
6. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin
and gut-derived resistin-like molecule-beta selectively impair insulin
action on glucose production. J Clin Invest 2003;111:225–30.
7. Yang RZ, Huang Q, Xu A, et al. Comparative studies of resistin
expression and phylogenomics in human and mouse. Biochem Biophys
Res Commun 2003;310:927–35.
8. Nakamura T, Funayama H, Kubo N, et al. Association of hyperadi-
ponectinemia with severity of ventricular dysfunction in congestive
heart failure. Circ J 2006;70:1557–62.
9. Engeli S, Sharma AM. The renin-angiotensin system and natri-
uretic peptides in obesity-associated hypertension. J Mol Med
2001;79:21–9.
0. Vincent HK, Powers SK, Stewart DJ, Shanely RA, Demirel H, Naito
H. Obesity is associated with increased myocardial oxidative stress. Int
J Obes Relat Metab Disord 1999;23:67–74.1. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese
44
4
4
4
4
K
762 Frankel et al. JACC Vol. 53, No. 9, 2009
Inflammatory Adipokines and HF March 3, 2009:754–62rats: implications for human obesity. Proc Natl Acad Sci U S A
2000;97:1784–9.
2. Dessi-Fulgheri P, Sarzani R, Rappelli A. The natriuretic peptide
system in obesity-related hypertension: new pathophysiological as-
pects. J Nephrol 1998;11:296–9.
3. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr.
Body-mass index and mortality in a prospective cohort of U.S. adults.
N Engl J Med 1999;341:1097–105.
4. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the
high-molecular weight form of adiponectin in plasma is useful for the
prediction of insulin resistance and metabolic syndrome. Diabetes
Care 2006;29:1357–62.
5. von Eynatten M, Lepper PM, Humpert PM. Total and high-
molecular weight adiponectin in relation to metabolic variables atevaluation of three assays: response to Bluher et al. Diabetes Care
2007;30:e67, author reply e68.
6. Aso Y, Yamamoto R, Wakabayashi S, et al. Comparison of serum
high-molecular weight (HMW) adiponectin with total adiponectin
concentrations in type 2 diabetic patients with coronary artery disease
using a novel enzyme-linked immunosorbent assay to detect HMW
adiponectin. Diabetes 2006;55:1954–60.
7. Bluher M, Brennan AM, Kelesidis T, et al. Total and high-molecular
weight adiponectin in relation to metabolic variables at baseline and in
response to an exercise treatment program: comparative evaluation of
three assays. Diabetes Care 2007;30:280–5.
ey Words: heart failure y resistin y adiponectin y adipokines y
baseline and in response to an exercise treatment program: comparative epidemiology.
